# Single-Dose Clinical Pharmacology Study in Asthmatic Adolescent and Adult Patients

> **NCT01803087** · PHASE2 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 60 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Test treatments CHF 1535 100/6 pMDI (Foster®) TEST1
- **DRUG:** CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ (TEST 2).
- **DRUG:** BDP pMDI 100 µg (Qvar®) plus formoterol fumarate pMDI 6 µg (Atimos®) (REF)
- **DRUG:** CHF 1535 100/6 pMDI (Foster®) (CTR)

## Key facts

- **NCT ID:** NCT01803087
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2020-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01803087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01803087, "Single-Dose Clinical Pharmacology Study in Asthmatic Adolescent and Adult Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01803087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*